Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 3/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | PRCP | P42785 | 3/20 | 0.40 |
| ▸ | MAOA | P21397 | 3/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19684816 | 1.00 | HTR2C (0.42) | HTR2CDRD2PARP1PRCPMAOA | |
| SCHEMBL7818489 | 1.00 | HTR2C (0.42) | HTR2CDRD2PARP1PRCPMAOA | |
| SCHEMBL19711049 | 0.80 | HTR2C (0.41) | HTR2CDRD2PARP1PRCPMAOA | |
| SCHEMBL1010276 | 0.80 | HTR2C (0.41) | HTR2CDRD2PARP1PRCPMAOA | |
| SCHEMBL30983663 | 0.80 | HTR2C (0.41) | HTR2CDRD2PARP1PRCPMAOA | |
| SCHEMBL19711053 | 0.80 | HTR2C (0.41) | HTR2CDRD2PARP1PRCPMAOA | |
| SCHEMBL19678842 | 0.77 | PARP1 (0.41) | HTR2CDRD2PARP1PRCPMAOA | |
| SCHEMBL19678841 | 0.77 | PARP1 (0.41) | HTR2CDRD2PARP1PRCPMAOA | |
| SCHEMBL12311985 | 0.77 | MAOA (0.53) | HTR2CDRD2MAOATSHRHSD17B10 | |
| SCHEMBL21651084 | 0.77 | PRCP (0.57) | DRD2PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | HTR2C 4759/4885DRD2 3868/4885PARP1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.